Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homologous and Heterologous COVID-19 Vaccine Boosting in Africa
NCT07408297Phase 2Completed
- Sponsor
- Victoria Biomedical Research Institute
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of Ad26.COV2.S, tozinameran, Sinopharm COVID-19 vaccine + Sinovac COVID-19 vaccine in coronavirus disease 2019 (COVID-19), sponsored by Victoria Biomedical Research Institute. Started May 2022; status: completed.
02
Drugs
Ad26.COV2.StozinameranSinopharm COVID-19 vaccine + Sinovac COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07408297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408297.